Extended-Release Buprenorphine vs. Sublingual Buprenorphine for the Treatment of Opioid Use Disorder
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The study is 12-week, randomized, open-label study comparing injectable extended-release
buprenorphine (Sublocade) to standard therapy (sublingual buprenorphine), to see if Sublocade
will be more helpful in treating opiate use for individuals testing positive for fentanyl and
related high potency drugs (HPSO). Those receiving Sublocade will have it administered
monthly and dosing will be according to the FDA prescribing instructions of 300mg for the
first and second dose and 100mg for the third. Individuals receiving sublingual buprenorphine
will receive standard dosing for the entire treatment trial. Participants will be asked to
attend the clinic for the first 4 days during week 1 and twice weekly for the remainder of
the trial.